// App-Quantinova.ai

CT014 : A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC)

Researchers

Presenter

  • Christopher J. Sweeney

Principal Investigators

  • Silke Gillessen

  • Dana Rathkopf

  • Nobuaki Matsubara

  • Charles Drake

  • Karim Fizazi

  • Josep M. Piulats

  • Piotr J. Wysocki

  • Gary L. Buchschacher

  • Jennifer Doss

  • Sanjeev Mariathasan

  • Edward E. Kadel

  • Kobe Yuen

  • Asim Datye

  • Grozdana Rasuo

  • Darren Tayama

  • Patrick Williams

  • Thomas Powles

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • National Cancer Center Hospital, Tokyo, Japan

  • Columbia University Medical Center, New York, NY

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

  • Institut Catal dOncologia-IDIBELL, Barcelona, Spain

  • Department of Biochemistry, Jagiellonian University Medical College, Krakow, Poland

  • Southern California Permanente Medical Group, Los Angeles Medical Center, Los Angeles, CA

  • Genentech, Inc., South San Francisico, CA

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Locations

  • United States

  • Switzerland

  • Japan

  • France

  • Spain

  • Poland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • Secondary liver cancer

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • Prostate specific antigen

  • Lactate dehydrogenase

Drug/Treatment

  • Atezolizumab

  • Enzalutamide

  • CB-7598

  • Docetaxel

  • Androgen Tear

  • taxane

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03016312

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved